{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:01:27Z","timestamp":1792598487430,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Antiplatelet therapy (AT) may serve to reduce the effects of aneurysmal subarachnoid hemorrhage (aSAH)-induced pro-coagulant state in the cerebral circulation. Several studies, however, have delivered conflicting conclusions on the efficacy of AT post aSAH. Systematic searches of Medline, Embase, and Cochrane Central were undertaken on 27th March 2023. The primary outcome was delayed cerebral ischaemia (DCI). Secondary outcomes were symptomatic and angiographic vasospasm, good functional outcome (modified Rankin Scale [mRS] with scores 0\u20132), hemorrhagic events, and in-hospital mortality. Twenty-two studies reporting 4378 patients with aSAH were included in the meta-analysis. AT was associated with lower rates of DCI (\n                    <jats:italic>RR<\/jats:italic>\n                    =0.62, 95% CI: 0.43; 0.89), symptomatic vasospasm (\n                    <jats:italic>RR<\/jats:italic>\n                    =0.63, 95% CI: 0.46; 0.86), and moderate\/severe angiographic vasospasm (\n                    <jats:italic>RR<\/jats:italic>\n                    =0.74, 95% CI: 0.65; 0.84), with no effect on hemorrhagic complications (\n                    <jats:italic>RR<\/jats:italic>\n                    =1.36, 95% CI: 0.77; 2.41). When analyzing only post-ictal use of AT, AT additionally favored rates of good functional outcomes (\n                    <jats:italic>RR<\/jats:italic>\n                    =1.18, 95% CI: 1.10; 1.26) and in-hospital mortality (\n                    <jats:italic>RR<\/jats:italic>\n                    =0.56, 95% CI: 0.39; 0.80). In the subgroup treated with cilostazol, AT was associated with lower rates of DCI (\n                    <jats:italic>RR<\/jats:italic>\n                    =0.40, 95% CI: 0.32), symptomatic vasospasm (\n                    <jats:italic>RR<\/jats:italic>\n                    =0.47, 95% CI: 0.33; 0.65), moderate\/severe angiographic vasospasm (\n                    <jats:italic>RR<\/jats:italic>\n                    =0.75, 95% CI: 0.57; 0.98) and good functional outcome (\n                    <jats:italic>RR<\/jats:italic>\n                    =1.24, 95% CI: 1.08; 1.43). In the surgically treated aSAH subgroup, AT favored rates of symptomatic vasospasm (\n                    <jats:italic>RR<\/jats:italic>\n                    =0.55, 95% CI: 0.30; 0.98), moderate\/severe angiographic vasospasm (\n                    <jats:italic>RR<\/jats:italic>\n                    =0.70, 95% CI: 0.54; 0.90) and good functional outcome (\n                    <jats:italic>RR<\/jats:italic>\n                    =1.23, 95% CI: 1.09; 1.41). In the endovascularly treated aSAH subgroup, AT was associated with lower rates of in-hospital mortality (\n                    <jats:italic>RR<\/jats:italic>\n                    =0.60, 95% CI: 0.41; 0.88). In aSAH patients, post-ictal AT is associated with benefits in terms of rates of DCI, vasospasm, good functional outcomes, and in-hospital mortality without an increased risk of hemorrhagic events.\n                  <\/jats:p>","DOI":"10.1007\/s10143-023-02120-2","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:01:35Z","timestamp":1693785695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Antiplatelet therapy in aneurysmal subarachnoid hemorrhage: an updated meta-analysis"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2308-0579","authenticated-orcid":false,"given":"Keng Siang","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2323-0973","authenticated-orcid":false,"given":"Cheyenne","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4353-4515","authenticated-orcid":false,"given":"Permesh S.","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramez","family":"Kirollos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5256-5669","authenticated-orcid":false,"given":"Vincent D.W.","family":"Nga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4376-5153","authenticated-orcid":false,"given":"Tseng Tsai","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6534-036X","authenticated-orcid":false,"given":"Hans","family":"Henkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-1613","authenticated-orcid":false,"given":"Adam S.","family":"Arthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4249-0402","authenticated-orcid":false,"given":"Leonard L.L.","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5514-5237","authenticated-orcid":false,"given":"Pervinder","family":"Bhogal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"issue":"4","key":"2120_CR1","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s10143-020-01420-1","volume":"44","author":"KS Lee","year":"2021","unstructured":"Lee KS et al (2021) Radiological surveillance of small unruptured intracranial aneurysms: a systematic review, meta-analysis, and meta-regression of 8428 aneurysms. Neurosurg Rev 44(4):2013\u20132023","journal-title":"Neurosurg Rev"},{"issue":"1","key":"2120_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10143-021-01543-z","volume":"45","author":"KS Lee","year":"2022","unstructured":"Lee KS et al (2022) The evolution of intracranial aneurysm treatment techniques and future directions. Neurosurg Rev 45(1):1\u201325","journal-title":"Neurosurg Rev"},{"issue":"6","key":"2120_CR3","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1161\/STR.0b013e3182587839","volume":"43","author":"ES Connolly","year":"2012","unstructured":"Connolly ES et al (2012) Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association\/american Stroke Association. Stroke 43(6):1711\u20131737","journal-title":"Stroke"},{"issue":"11","key":"2120_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJM198303173081103","volume":"308","author":"GS Allen","year":"1983","unstructured":"Allen GS et al (1983) Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 308(11):619\u2013624","journal-title":"N Engl J Med"},{"issue":"1","key":"2120_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1161\/STROKEAHA.117.017956","volume":"49","author":"CS Gathier","year":"2018","unstructured":"Gathier CS et al (2018) Induced hypertension for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a randomized clinical trial. Stroke 49(1):76\u201383","journal-title":"Stroke"},{"issue":"4","key":"2120_CR6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1161\/STROKEAHA.110.597914","volume":"42","author":"MD Vergouwen","year":"2011","unstructured":"Vergouwen MD, Ilodigwe D, Macdonald RL (2011) Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and -independent effects. Stroke 42(4):924\u2013929","journal-title":"Stroke"},{"issue":"12","key":"2120_CR7","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/jnnp-2014-307711","volume":"85","author":"KP Budohoski","year":"2014","unstructured":"Budohoski KP et al (2014) The pathophysiology and treatment of delayed cerebral ischaemia following subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 85(12):1343\u20131353","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"2120_CR8","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1212\/WNL.54.4.872","volume":"54","author":"JW Hop","year":"2000","unstructured":"Hop JW et al (2000) Randomized pilot trial of postoperative aspirin in subarachnoid hemorrhage. Neurology 54(4):872\u2013878","journal-title":"Neurology"},{"issue":"3","key":"2120_CR9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3171\/jns.1991.74.3.0386","volume":"74","author":"S Juvela","year":"1991","unstructured":"Juvela S, Hillbom M, Kaste M (1991) Platelet thromboxane release and delayed cerebral ischemia in patients with subarachnoid hemorrhage. J Neurosurg 74(3):386\u2013392","journal-title":"J Neurosurg"},{"issue":"4","key":"2120_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/01.STR.22.4.451","volume":"22","author":"S Juvela","year":"1991","unstructured":"Juvela S et al (1991) Angiographic vasospasm and release of platelet thromboxane after subarachnoid hemorrhage. Stroke 22(4):451\u2013455","journal-title":"Stroke"},{"issue":"7","key":"2120_CR11","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1161\/01.STR.22.7.854","volume":"22","author":"H Ohkuma","year":"1991","unstructured":"Ohkuma H et al (1991) Role of platelet function in symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke 22(7):854\u2013859","journal-title":"Stroke"},{"issue":"3","key":"2120_CR12","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3171\/2017.5.JNS17831","volume":"129","author":"Y Nagahama","year":"2018","unstructured":"Nagahama Y et al (2018) Dual antiplatelet therapy in aneurysmal subarachnoid hemorrhage: association with reduced risk of clinical vasospasm and delayed cerebral ischemia. J Neurosurg 129(3):702\u2013710","journal-title":"J Neurosurg"},{"issue":"6","key":"2120_CR13","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/neuros\/nyy550","volume":"85","author":"M Darkwah Oppong","year":"2019","unstructured":"Darkwah Oppong M et al (2019) Post-treatment antiplatelet therapy reduces risk for delayed cerebral ischemia due to aneurysmal subarachnoid hemorrhage. Neurosurgery 85(6):827\u2013833","journal-title":"Neurosurgery"},{"key":"2120_CR14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"10","key":"2120_CR15","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1161\/STROKEAHA.110.589275","volume":"41","author":"MD Vergouwen","year":"2010","unstructured":"Vergouwen MD et al (2010) Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke 41(10):2391\u20132395","journal-title":"Stroke"},{"key":"2120_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.wneu.2021.09.034","volume":"161","author":"KS Lee","year":"2022","unstructured":"Lee KS et al (2022) Tenets for the proper conduct and use of meta-analyses: a practical guide for neurosurgeons. World Neurosurg 161:291\u2013302.e1","journal-title":"World Neurosurg"},{"issue":"1","key":"2120_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12874-021-01269-y","volume":"21","author":"C Lunny","year":"2021","unstructured":"Lunny C et al (2021) Managing overlap of primary study results across systematic reviews: practical considerations for authors of overviews of reviews. BMC Med Res Methodol 21(1):140","journal-title":"BMC Med Res Methodol"},{"issue":"7524","key":"2120_CR18","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/bmj.38636.593461.68","volume":"331","author":"T Greenhalgh","year":"2005","unstructured":"Greenhalgh T, Peacock R (2005) Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources. BMJ 331(7524):1064\u20131065","journal-title":"BMJ"},{"issue":"3","key":"2120_CR19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jrsm.1348","volume":"10","author":"G Schwarzer","year":"2019","unstructured":"Schwarzer G et al (2019) Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Res Synth Methods 10(3):476\u2013483","journal-title":"Res Synth Methods"},{"key":"2120_CR20","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.2","author":"JP Higgins","year":"2021","unstructured":"Higgins JP, Thomas J, Chandler J (2021) Cochrane handbook for systematic reviews of interventions version 6.2. Cochrane"},{"issue":"1","key":"2120_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5(1):13","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"2120_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X et al (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14(1):135","journal-title":"BMC Med Res Methodol"},{"issue":"7650","key":"2120_CR23","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926","journal-title":"BMJ"},{"key":"2120_CR24","doi-asserted-by":"publisher","first-page":"107022","DOI":"10.1016\/j.clineuro.2021.107022","volume":"211","author":"F Al-Mufti","year":"2021","unstructured":"Al-Mufti F et al (2021) Impact of pre-ictal antiplatelet therapy use in aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg 211:107022","journal-title":"Clin Neurol Neurosurg"},{"key":"2120_CR25","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/j.wneu.2018.01.188","volume":"113","author":"M Bruder","year":"2018","unstructured":"Bruder M et al (2018) Continuous acetylsalicylic acid treatment does not influence bleeding pattern or outcome of aneurysmal subarachnoid hemorrhage: a matched-pair analysis. World Neurosurg 113:e122\u2013e128","journal-title":"World Neurosurg"},{"issue":"5","key":"2120_CR26","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1007\/s10143-021-01477-6","volume":"44","author":"C Ditz","year":"2021","unstructured":"Ditz C et al (2021) Effects of post-interventional antiplatelet therapy on angiographic vasospasm, delayed cerebral ischemia, and clinical outcome after aneurysmal subarachnoid hemorrhage: a single-center experience. Neurosurg Rev 44(5):2899\u20132912","journal-title":"Neurosurg Rev"},{"key":"2120_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-3-319-04981-6_25","volume":"120","author":"H Kimura","year":"2015","unstructured":"Kimura H et al (2015) Cilostazol administration with combination enteral and parenteral nutrition therapy remarkably improves outcome after subarachnoid hemorrhage. Acta Neurochir Suppl 120:147\u2013152","journal-title":"Acta Neurochir Suppl"},{"issue":"1-2","key":"2120_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000445509","volume":"42","author":"N Matsuda","year":"2016","unstructured":"Matsuda N et al (2016) Effect of cilostazol on cerebral vasospasm and outcome in patients with aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled trial. Cerebrovasc Dis 42(1-2):97\u2013105","journal-title":"Cerebrovasc Dis"},{"issue":"2","key":"2120_CR29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3171\/2016.5.JNS152907","volume":"127","author":"Y Nakatsuka","year":"2017","unstructured":"Nakatsuka Y et al (2017) Preventive effects of cilostazol against the development of shunt-dependent hydrocephalus after subarachnoid hemorrhage. J Neurosurg 127(2):319\u2013326","journal-title":"J Neurosurg"},{"issue":"5","key":"2120_CR30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1177\/17474930211035647","volume":"17","author":"M Seb\u00f6k","year":"2022","unstructured":"Seb\u00f6k M et al (2022) Prehemorrhage antiplatelet use in aneurysmal subarachnoid hemorrhage and impact on clinical outcome. Int J Stroke 17(5):545\u2013552","journal-title":"Int J Stroke"},{"issue":"1","key":"2120_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3171\/2012.9.JNS12492","volume":"118","author":"N Senbokuya","year":"2013","unstructured":"Senbokuya N et al (2013) Effects of cilostazol on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a multicenter prospective, randomized, open-label blinded end point trial. J Neurosurg 118(1):121\u2013130","journal-title":"J Neurosurg"},{"issue":"6","key":"2120_CR32","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ana.25361","volume":"84","author":"K Sugimoto","year":"2018","unstructured":"Sugimoto K et al (2018) Cilostazol decreases duration of spreading depolarization and spreading ischemia after aneurysmal subarachnoid hemorrhage. Ann Neurol 84(6):873\u2013885","journal-title":"Ann Neurol"},{"issue":"3","key":"2120_CR33","doi-asserted-by":"publisher","first-page":"134","DOI":"10.7461\/jcen.2020.22.3.134","volume":"22","author":"GU Sun","year":"2020","unstructured":"Sun GU et al (2020) Dual antiplatelet treatment associated with reduced risk of symptomatic vasospasm and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage. J Cerebrovasc Endovasc Neurosurg 22(3):134\u2013140","journal-title":"J Cerebrovasc Endovasc Neurosurg"},{"issue":"2","key":"2120_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/01616412.1989.11739867","volume":"11","author":"S Suzuki","year":"1989","unstructured":"Suzuki S et al (1989) Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture: a randomized double-blind study. Neurol Res 11(2):79\u201388","journal-title":"Neurol Res"},{"issue":"1","key":"2120_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000327040","volume":"32","author":"S Suzuki","year":"2011","unstructured":"Suzuki S et al (2011) Cilostazol improves outcome after subarachnoid hemorrhage: a preliminary report. Cerebrovasc Dis 32(1):89\u201393","journal-title":"Cerebrovasc Dis"},{"issue":"2","key":"2120_CR36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/0090-3019(91)90228-2","volume":"36","author":"K Tokiyoshi","year":"1991","unstructured":"Tokiyoshi K, Ohnishi T, Nii Y (1991) Efficacy and toxicity of thromboxane synthetase inhibitor for cerebral vasospasm after subarachnoid hemorrhage. Surg Neurol 36(2):112\u2013118","journal-title":"Surg Neurol"},{"issue":"6","key":"2120_CR37","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3171\/jns.2004.101.6.0921","volume":"101","author":"LG Toussaint","year":"2004","unstructured":"Toussaint LG et al (2004) Influence of aspirin on outcome following aneurysmal subarachnoid hemorrhage. J Neurosurg 101(6):921\u2013925","journal-title":"J Neurosurg"},{"issue":"9","key":"2120_CR38","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1161\/01.STR.0000236841.16055.0f","volume":"37","author":"WM van den Bergh","year":"2006","unstructured":"van den Bergh WM et al (2006) Randomized controlled trial of acetylsalicylic acid in aneurysmal subarachnoid hemorrhage: the MASH study. Stroke 37(9):2326\u20132330","journal-title":"Stroke"},{"issue":"1-4","key":"2120_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/BF01401822","volume":"125","author":"K Yano","year":"1993","unstructured":"Yano K et al (1993) Preventive therapy against delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage: trials of thromboxane A2 synthetase inhibitor and hyperdynamic therapy. Acta Neurochir 125(1-4):15\u201319","journal-title":"Acta Neurochir"},{"issue":"5","key":"2120_CR40","doi-asserted-by":"publisher","first-page":"E552","DOI":"10.1093\/neuros\/nyaa170","volume":"87","author":"M Zanaty","year":"2020","unstructured":"Zanaty M et al (2020) Tirofiban protocol protects against delayed cerebral ischemia: a case-series study. Neurosurgery 87(5):E552\u2013E556","journal-title":"Neurosurgery"},{"key":"2120_CR41","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1016\/j.wneu.2019.09.149","volume":"133","author":"N Shimamura","year":"2020","unstructured":"Shimamura N et al (2020) Use of preprocedural, multiple antiplatelet medications for coil embolization of ruptured cerebral aneurysm in the acute stage improved clinical outcome and reduced thromboembolic complications without hemorrhagic complications. World Neurosurg 133:e751\u2013e756","journal-title":"World Neurosurg"},{"issue":"1","key":"2120_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/001316446002000104","volume":"20","author":"J Cohen","year":"1960","unstructured":"Cohen J (1960) A coefficient of agreement for nominal scales. Educ Psychol Meas 20(1):37\u201347","journal-title":"Educ Psychol Meas"},{"issue":"6","key":"2120_CR43","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3171\/jns.1995.82.6.0945","volume":"82","author":"S Juvela","year":"1995","unstructured":"Juvela S (1995) Aspirin and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Neurosurg 82(6):945\u2013952","journal-title":"J Neurosurg"},{"issue":"7","key":"2120_CR44","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.3174\/ajnr.A6086","volume":"40","author":"F Cagnazzo","year":"2019","unstructured":"Cagnazzo F et al (2019) Antiplatelet therapy in patients with aneurysmal SAH: impact on delayed cerebral ischemia and clinical outcome. A meta-analysis. AJNR Am J Neuroradiol 40(7):1201\u20131206","journal-title":"AJNR Am J Neuroradiol"},{"key":"2120_CR45","doi-asserted-by":"crossref","unstructured":"Snyder MH et al (2022) Antiplatelet therapy and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Neurosurg 137(1):95\u2013107","DOI":"10.3171\/2021.7.JNS211239"},{"issue":"9","key":"2120_CR46","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1161\/01.STR.0000083621.44269.3E","volume":"34","author":"SM Dorhout Mees","year":"2003","unstructured":"Dorhout Mees SM et al (2003) Antiplatelet therapy in aneurysmal subarachnoid hemorrhage: a systematic review. Stroke 34(9):2285\u20132289","journal-title":"Stroke"},{"issue":"4","key":"2120_CR47","first-page":"CD006184","volume":"2007","author":"SM Dorhout Mees","year":"2007","unstructured":"Dorhout Mees SM et al (2007) Antiplatelet therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007(4):CD006184","journal-title":"Cochrane Database Syst Rev"},{"issue":"9488","key":"2120_CR48","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0140-6736(05)67214-5","volume":"366","author":"AJ Molyneux","year":"2005","unstructured":"Molyneux AJ et al (2005) International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet 366(9488):809\u2013817","journal-title":"Lancet"},{"issue":"4","key":"2120_CR49","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00415-011-6243-2","volume":"259","author":"SM Dorhout Mees","year":"2012","unstructured":"Dorhout Mees SM et al (2012) Occurrence and impact of delayed cerebral ischemia after coiling and after clipping in the International Subarachnoid Aneurysm Trial (ISAT). J Neurol 259(4):679\u2013683","journal-title":"J Neurol"},{"key":"2120_CR50","doi-asserted-by":"crossref","unstructured":"Li R et al (2021) In-hospital complication-related risk factors for discharge and 90-day outcomes in patients with aneurysmal subarachnoid hemorrhage after surgical clipping and endovascular coiling: a propensity score-matched analysis. J Neurosurg:1\u201312","DOI":"10.3171\/2021.10.JNS211484"},{"issue":"1","key":"2120_CR51","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/15910199211015042","volume":"28","author":"RJ Borchert","year":"2022","unstructured":"Borchert RJ et al (2022) P2Y12 inhibitors for the neurointerventionalist. Interv Neuroradiol 28(1):92\u2013103","journal-title":"Interv Neuroradiol"},{"issue":"6","key":"2120_CR52","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1161\/STROKEAHA.108.528802","volume":"40","author":"WM van den Bergh","year":"2009","unstructured":"van den Bergh WM et al (2009) Effect of antiplatelet therapy for endovascular coiling in aneurysmal subarachnoid hemorrhage. Stroke 40(6):1969\u20131972","journal-title":"Stroke"},{"issue":"2","key":"2120_CR53","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00415-009-0057-5","volume":"256","author":"WM van den Bergh","year":"2009","unstructured":"van den Bergh WM et al (2009) Magnesium and aspirin treatment in patients with subarachnoid haemorrhage. Comparison of effects after endovascular and neurosurgical aneurysm occlusion. J Neurol 256(2):213\u2013216","journal-title":"J Neurol"},{"issue":"2","key":"2120_CR54","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/neurintsurg-2014-011570","volume":"8","author":"P Bhogal","year":"2016","unstructured":"Bhogal P, Brouwer PA, Makalanda HL (2016) Cilostazol: an antiplatelet agent for the neurointerventionist? J Neurointerv Surg 8(2):208\u2013209","journal-title":"J Neurointerv Surg"},{"issue":"4","key":"2120_CR55","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40265-015-0364-3","volume":"75","author":"KC Rogers","year":"2015","unstructured":"Rogers KC, Oliphant CS, Finks SW (2015) Clinical efficacy and safety of cilostazol: a critical review of the literature. Drugs 75(4):377\u2013395","journal-title":"Drugs"},{"issue":"12","key":"2120_CR56","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1097\/01.WCB.0000143536.22131.D7","volume":"24","author":"S Birk","year":"2004","unstructured":"Birk S et al (2004) The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 24(12):1352\u20131358","journal-title":"J Cereb Blood Flow Metab"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-023-02120-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-023-02120-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-023-02120-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T13:12:44Z","timestamp":1705929164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-023-02120-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2120"],"URL":"https:\/\/doi.org\/10.1007\/s10143-023-02120-2","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"assertion":[{"value":"15 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}